Abstract
Alternative terminology for melanoma in situ may reduce anxiety and preference for further surgery, while having little effect on preferences for clinical surveillance. We argue that lesion-level prognosis and patient-level future melanoma risk should be considered separately, so that de-escalation of treatment is not automatically equated with de-escalation of risk-based follow-up.